Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under ...

The study tests Dupilumab, a subcutaneous injection, against a placebo. Dupilumab is designed to treat asthma by targeting specific pathways involved in the inflammatory process.

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...